Cargando…

A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy

BACKGROUND: Diabetic retinopathy (DR) includes a series of typical lesions affected by retinal microvascular damage caused by diabetes mellitus (DM), which not only seriously damages the vision, affecting the life's quality of patients, but also brings a considerable burden to the family and so...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Qi, Hao, Xiao-Feng, Xie, Li-Ke, Xu, Jing, Sun, Mei, Yuan, Hang, Wang, Shi-Hui, Wu, Gai-Ping, Miao, Meng-Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652614/
https://www.ncbi.nlm.nih.gov/pubmed/33204295
http://dx.doi.org/10.1155/2020/8878569
_version_ 1783607725938180096
author Jin, Qi
Hao, Xiao-Feng
Xie, Li-Ke
Xu, Jing
Sun, Mei
Yuan, Hang
Wang, Shi-Hui
Wu, Gai-Ping
Miao, Meng-Lu
author_facet Jin, Qi
Hao, Xiao-Feng
Xie, Li-Ke
Xu, Jing
Sun, Mei
Yuan, Hang
Wang, Shi-Hui
Wu, Gai-Ping
Miao, Meng-Lu
author_sort Jin, Qi
collection PubMed
description BACKGROUND: Diabetic retinopathy (DR) includes a series of typical lesions affected by retinal microvascular damage caused by diabetes mellitus (DM), which not only seriously damages the vision, affecting the life's quality of patients, but also brings a considerable burden to the family and society. Astragalus Membranaceus (AM) is a commonly used medicine in clinical therapy of eye disorders in traditional Chinese medicine (TCM). In recent years, it is also used for treating DR, but the specific mechanism is unclear. Therefore, this study explores the potential mechanism of AM in DR treatment by using network pharmacology. METHODS: Based on the oral bioavailability (OB) and drug likeness (DL) of two ADME (absorption, distribution, metabolism, excretion) parameters, Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), Swiss Target Prediction platform, GeneCards, and OMIM database were used to predict and screen the active compounds of AM, the core targets of AM in DR treatment. The Metascape data platform was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis on the core targets. RESULTS: 24 active compounds were obtained, such as quercetin, kaempferol, and astragaloside IV. There were 169 effective targets of AM in DR treatment, and the targets were further screened and finally, 38 core targets were obtained, such as VEGFA, AKT1, and IL-6. EGFR tyrosine kinase inhibitor resistance, AGE-RAGE signaling pathway in diabetic complications, PI3K-Akt signaling pathway, and other metabolic pathways participated in oxidative stress, cell apoptosis, angiogenesis signal transduction, inflammation, and other biological processes. CONCLUSION: AM treats DR through multiple compounds, multiple targets, and multiple pathways. AM may play a role in the treatment of DR by targeting VEGFA, AKT1, and IL-6 and participating in oxidative stress, angiogenesis, and inflammation.
format Online
Article
Text
id pubmed-7652614
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-76526142020-11-16 A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy Jin, Qi Hao, Xiao-Feng Xie, Li-Ke Xu, Jing Sun, Mei Yuan, Hang Wang, Shi-Hui Wu, Gai-Ping Miao, Meng-Lu Evid Based Complement Alternat Med Research Article BACKGROUND: Diabetic retinopathy (DR) includes a series of typical lesions affected by retinal microvascular damage caused by diabetes mellitus (DM), which not only seriously damages the vision, affecting the life's quality of patients, but also brings a considerable burden to the family and society. Astragalus Membranaceus (AM) is a commonly used medicine in clinical therapy of eye disorders in traditional Chinese medicine (TCM). In recent years, it is also used for treating DR, but the specific mechanism is unclear. Therefore, this study explores the potential mechanism of AM in DR treatment by using network pharmacology. METHODS: Based on the oral bioavailability (OB) and drug likeness (DL) of two ADME (absorption, distribution, metabolism, excretion) parameters, Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), Swiss Target Prediction platform, GeneCards, and OMIM database were used to predict and screen the active compounds of AM, the core targets of AM in DR treatment. The Metascape data platform was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis on the core targets. RESULTS: 24 active compounds were obtained, such as quercetin, kaempferol, and astragaloside IV. There were 169 effective targets of AM in DR treatment, and the targets were further screened and finally, 38 core targets were obtained, such as VEGFA, AKT1, and IL-6. EGFR tyrosine kinase inhibitor resistance, AGE-RAGE signaling pathway in diabetic complications, PI3K-Akt signaling pathway, and other metabolic pathways participated in oxidative stress, cell apoptosis, angiogenesis signal transduction, inflammation, and other biological processes. CONCLUSION: AM treats DR through multiple compounds, multiple targets, and multiple pathways. AM may play a role in the treatment of DR by targeting VEGFA, AKT1, and IL-6 and participating in oxidative stress, angiogenesis, and inflammation. Hindawi 2020-11-02 /pmc/articles/PMC7652614/ /pubmed/33204295 http://dx.doi.org/10.1155/2020/8878569 Text en Copyright © 2020 Qi Jin et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jin, Qi
Hao, Xiao-Feng
Xie, Li-Ke
Xu, Jing
Sun, Mei
Yuan, Hang
Wang, Shi-Hui
Wu, Gai-Ping
Miao, Meng-Lu
A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy
title A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy
title_full A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy
title_fullStr A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy
title_full_unstemmed A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy
title_short A Network Pharmacology to Explore the Mechanism of Astragalus Membranaceus in the Treatment of Diabetic Retinopathy
title_sort network pharmacology to explore the mechanism of astragalus membranaceus in the treatment of diabetic retinopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652614/
https://www.ncbi.nlm.nih.gov/pubmed/33204295
http://dx.doi.org/10.1155/2020/8878569
work_keys_str_mv AT jinqi anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT haoxiaofeng anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT xielike anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT xujing anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT sunmei anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT yuanhang anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT wangshihui anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT wugaiping anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT miaomenglu anetworkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT jinqi networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT haoxiaofeng networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT xielike networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT xujing networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT sunmei networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT yuanhang networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT wangshihui networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT wugaiping networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy
AT miaomenglu networkpharmacologytoexplorethemechanismofastragalusmembranaceusinthetreatmentofdiabeticretinopathy